Mylan received a U.S. Tax Court order to turn over documents to the IRS relating to a controversial licensing deal with Forest Laboratories.

In 2014, the IRS issued the drugmaker a $100 million tax bill over the 2008 agreement with Forest. Mylan said the transaction should be classified as a sale rather than a licensing agreement.

In January, IRS officials filed a motion to order Mylan to produce the relevant documents, arguing the company was acting in bad faith and had refused several prior requests for information.